High N-Terminal Pro–B-Type Natriuretic Peptide: A Biomarker of Lung Cancer?

High N-Terminal Pro–B-Type Natriuretic Peptide: A Biomarker of Lung Cancer?

Abstract Background The level of N-terminal pro–B-type natriuretic peptide (NT-proBNP) is affected by many known factors. Our study aimed to evaluate whether other factors, in particular lung cancer, could be responsible for an increase in NT-proBNP levels in a population with no known risk factors...

Full description

Saved in:
Bibliographic Details
Published in:Clinical lung cancer Vol. 11; no. 5; pp. 341 - 345
Main Authors: Aujollet, Nathalie, Meyer, Marjorie, Cailliod, Romain, Combier, Fanny, Coignet, Yann, Campard, Sebastien, Facy, Olivier, Bernard, Alain, Girard, Claude
Format: Journal Article
Language:English
Published: United States Elsevier Inc 01-09-2010
Subjects:
Aged
Atrial fibrillation
Biomarkers - metabolism
C-Reactive Protein - metabolism
Cardiac biomarker
Dysthyroidy
Female
Hematology, Oncology and Palliative Medicine
Humans
Lung Neoplasms - metabolism
Male
Middle Aged
Natriuretic Peptide, Brain - metabolism
NT-proBNP
Peptide Fragments - metabolism
Pulmonary/Respiratory
Regression Analysis
Risk Factors
ROC Curve
Cardiac biomarker
Dysthyroidy
NT-proBNP
Atrial fibrillation
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background The level of N-terminal pro–B-type natriuretic peptide (NT-proBNP) is affected by many known factors. Our study aimed to evaluate whether other factors, in particular lung cancer, could be responsible for an increase in NT-proBNP levels in a population with no known risk factors for elevated NT-proBNP. Patients and Methods This study was based on the RIABO (Recueil de l’Ischémie au Bloc Opératoire) database, a single-center registry that prospectively records in elective noncardiac surgery. Patients aged > 75 years and those presenting with 1 or more known risk factors for high NT-proBNP were excluded. Patients were divided into 2 groups according to preoperative NT-proBNP levels: (≥ 125 pg/mL or < 125 pg/mL). Results Between October 2005 and February 2007, 439 patients were eligible for inclusion. Among 35 patients with lung cancer, 26 (74%) had elevated NT-proBNP (≥ 125 pg/mL), versus 9 (26%) with NT-proBNP < 125 pg/mL ( P < .0001). By multivariate analysis, the presence of lung cancer was an independent risk factor for a level of NT-proBNP ≥ 125 pg/mL (odds ratio, 7; 95% CI, 2.9-17; P < .0001). We also observed an independent relationship between NT-proBNP ≥ 125 pg/mL and age, female sex, smoking status, and C-reactive protein levels. Conclusion In our study, patients with lung cancer were 7 times more likely to have elevated NT-proBNP (≥ 125 pg/mL). The presence of lung cancer should therefore be taken into account when interpreting NT-proBNP levels. Further studies are warranted to explore the diagnostic value of this marker in lung cancer and to identify the cause of the elevation.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1525-7304
1938-0690
DOI:10.3816/CLC.2010.n.043